Frazier Life Sciences Management L.P. Acquires 3,469,210 Shares of Lexeo Therapeutics, Inc. $LXEO

Frazier Life Sciences Management L.P. grew its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 363.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,424,725 shares of the company’s stock after acquiring an additional 3,469,210 shares during the quarter. Lexeo Therapeutics accounts for 0.7% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 29th largest holding. Frazier Life Sciences Management L.P. owned approximately 0.13% of Lexeo Therapeutics worth $17,787,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of LXEO. Vanguard Personalized Indexing Management LLC bought a new stake in Lexeo Therapeutics in the 2nd quarter valued at $60,000. Savant Capital LLC acquired a new position in Lexeo Therapeutics in the 2nd quarter valued at approximately $119,000. Ethic Inc. bought a new stake in shares of Lexeo Therapeutics in the 2nd quarter worth approximately $44,000. Affinity Asset Advisors LLC acquired a new stake in shares of Lexeo Therapeutics during the 1st quarter worth approximately $5,139,000. Finally, Palumbo Wealth Management LLC bought a new stake in shares of Lexeo Therapeutics during the second quarter valued at approximately $226,000. Institutional investors own 60.67% of the company’s stock.

Insider Buying and Selling

In other news, insider Eric Adler sold 3,382 shares of the stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $30,235.08. Following the sale, the insider owned 73,261 shares in the company, valued at approximately $654,953.34. This represents a 4.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tai Sandi See sold 3,888 shares of the firm’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $34,758.72. Following the completion of the sale, the insider owned 65,862 shares of the company’s stock, valued at approximately $588,806.28. This trade represents a 5.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 24,646 shares of company stock worth $221,037 in the last three months. Insiders own 5.30% of the company’s stock.

Lexeo Therapeutics Stock Down 0.3%

Shares of LXEO stock opened at $9.77 on Friday. Lexeo Therapeutics, Inc. has a 12-month low of $1.45 and a 12-month high of $10.38. The company has a market capitalization of $713.08 million, a P/E ratio of -3.62 and a beta of 1.76. The firm has a 50-day moving average price of $9.06 and a 200 day moving average price of $6.15.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.15. As a group, research analysts expect that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Analysts Set New Price Targets

LXEO has been the subject of several research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday. Guggenheim assumed coverage on shares of Lexeo Therapeutics in a research note on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research report on Wednesday, October 8th. Leerink Partners increased their price target on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Lexeo Therapeutics in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $18.63.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.